FUSION ANTIBODIES PLC

• ⚠

  Material uncertainty over going concern

  the Directors believe that there exists a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern and it may be unable to realise its assets and discharge its liabilities in the normal course of business.

1. FUSION ANTIBODIES PLC 2017-12-11 → present
2. FUSION ANTIBODIES LIMITED 2000-11-29 → 2017-12-11

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Kreston Reeves LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“the Directors believe that there exists a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern and it may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Significant events

• “Audited revenues for FY2025 of £1.97m (FY2024: £1.14m)”
• “Increased activity in the second half of FY2025 including the continuation of the collaboration agreement with the National Cancer Institute for the use of OptiMAL®”
• “Placing announced in March 2025, raising £1.17m (before expenses) for general working capital and investment into commercial activities”
• “Significant increase in sales pipeline opportunities during H2 FY2025.”
• “Cash position as at 31 March 2025 of £0.4m (31 March 2024: £1.2m)”
• “award of the Future Medicines Institute (FMI) grant announced by the Company in December 2024.”
• “The equity fundraise, announced on 18 March 2025, raised approximately £1.17m (before expenses) by way of a placing”
• “On 7 April 2025, at the Company's general meeting, all resolutions in connection with the issue of the 8,416,020 second tranche placing shares were approved. As a result, the 8,416,020 second tranche placing shares were issued and admitted to trading on AIM on 9 April 2025, completing the approximately £1.17m raise (before expenses).”
• “On 24 April 2025, the Company announced the approval of an Innovate UK Launchpad grant led by the Company in collaboration with Queen's University Belfast ("QUB") to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers.”
• “We were excited to announce on 5 August 2025 that the United States Patent and Trademark Office has granted the Company's U.S. OptiMAL® patent application.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

4

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +73%

  £1,136,000 → £1,965,000

• Cash

  -70.1%

  £1,199,000 → £359,000

• Net assets

  -62.7%

  £1,793,000 → £669,000

• Employees

  -22.6%

  31 → 24

• Operating profit

  +22.2%

  -£2,288,000 → -£1,779,000

• Profit before tax

  +22.4%

  -£2,289,000 → -£1,777,000

• Wages

  -13.4%

  £1,191,000 → £1,032,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers